Literature DB >> 8506190

Subcutaneous versus intravenous administration of heparin in the treatment of deep vein thrombosis; which do patients prefer? A randomized cross-over study.

A M Robinson1, K A McLean, M Greaves, K S Channer.   

Abstract

Patient preference for intravenous or subcutaneous heparin in the treatment of deep venous thrombosis was assessed in a randomized cross-over study. Twenty patients with venographically proven deep venous thrombosis were randomized to receive subcutaneous or intravenous heparin for 3 days followed by 3 days of the other treatment. Discomfort at the injection site, assessed by visual analogue scale, was significantly less for the subcutaneous than the intravenous administration route (P < 0.001), mobility was thought to be better when receiving subcutaneous heparin (P < 0.005) and patients' overall preference was for subcutaneous treatment (P < 0.001).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8506190      PMCID: PMC2399638          DOI: 10.1136/pgmj.69.808.115

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  5 in total

1.  An objective study of alternative methods of heparin administration.

Authors:  P G Bentley; V V Kakkar; M F Scully; I R MacGregor; P Webb; P Chan; N Jones
Journal:  Thromb Res       Date:  1980 Apr 1-15       Impact factor: 3.944

2.  Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomised trial.

Authors:  M G Walker; J W Shaw; G J Thomson; J G Cumming; M L Thomas
Journal:  Br Med J (Clin Res Ed)       Date:  1987-05-09

3.  Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial.

Authors:  D J Doyle; A G Turpie; J Hirsh; C Best; D Kinch; M N Levine; M Gent
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

4.  Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis.

Authors:  D W Hommes; A Bura; L Mazzolai; H R Büller; J W ten Cate
Journal:  Ann Intern Med       Date:  1992-02-15       Impact factor: 25.391

5.  Subcutaneous administration of heparin. A randomised comparison with intravenous administration of heparin to patients with deep-vein thrombosis.

Authors:  G Andersson; B Fagrell; K Holmgren; H Johnsson; B Ljungberg; E Nilsson; S Wilhelmsson; S Zetterquist
Journal:  Thromb Res       Date:  1982-09-15       Impact factor: 3.944

  5 in total
  5 in total

Review 1.  Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease.

Authors:  Katharine Ker; Gavin Tansley; Deirdre Beecher; Anders Perner; Haleema Shakur; Tim Harris; Ian Roberts
Journal:  Cochrane Database Syst Rev       Date:  2015-02-26

2.  Patient values and preferences regarding VTE disease: a systematic review to inform American Society of Hematology guidelines.

Authors:  Itziar Etxeandia-Ikobaltzeta; Yuan Zhang; Francesca Brundisini; Ivan D Florez; Wojtek Wiercioch; Robby Nieuwlaat; Housne Begum; Carlos A Cuello; Yetiani Roldan; Ru Chen; Chengyi Ding; Rebecca L Morgan; John J Riva; Yuqing Zhang; Rana Charide; Arnav Agarwal; Sara Balduzzi; Gian Paolo Morgano; Juan José Yepes-Nuñez; Yasir Rehman; Ignacio Neumann; Nicole Schwab; Tejan Baldeh; Cody Braun; María Francisca Rodríguez; Holger J Schünemann
Journal:  Blood Adv       Date:  2020-03-10

3.  Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.

Authors:  Kelly L Stoner; Helena Harder; Lesley J Fallowfield; Valerie A Jenkins
Journal:  Patient       Date:  2014-07-12       Impact factor: 3.883

Review 4.  The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.

Authors:  Jing-Fen Jin; Ling-Ling Zhu; Meng Chen; Hui-Min Xu; Hua-Fen Wang; Xiu-Qin Feng; Xiu-Ping Zhu; Quan Zhou
Journal:  Patient Prefer Adherence       Date:  2015-07-02       Impact factor: 2.711

5.  Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases.

Authors:  Louis S Matza; Ze Cong; Karen Chung; Alison Stopeck; Katia Tonkin; Janet Brown; Ada Braun; Kate Van Brunt; Kelly McDaniel
Journal:  Patient Prefer Adherence       Date:  2013-08-29       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.